Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 11.70m |
Free float | 11.64m |
P/E (TTM) | -- |
Market cap | 329.95m USD |
EPS (TTM) | -2.22 USD |
Annual div (ADY) | 2.00 EUR |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Jul 03 2024 |
Div pay-date | Jul 15 2024 |
Data delayed at least 15 minutes.
More ▼
Announcements
- XOMA Royalty to Present at Upcoming Investor Conferences in September
- XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
- XOMA Declares Quarterly Preferred Stock Dividends
- XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
- XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
- XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
- XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
- XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
- XOMA Corporation Announces Closing of Tender Offer
- XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
More ▼